Entrada Therapeutics Inc (TRDA)
17.24
-0.80
(-4.46%)
USD |
NASDAQ |
Jan 07, 15:51
Entrada Therapeutics SG&A Expense (Quarterly): 9.971M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 45.88M |
| Vertex Pharmaceuticals Inc | 371.80M |
| Sarepta Therapeutics Inc | 128.20M |
| Regenxbio Inc | 19.42M |
| Edgewise Therapeutics Inc | 8.21M |